Oncotype DX Breast Recurrence Score

Interpreting the Results

Genomic Health makes understanding Oncotype DX Breast Recurrence Score test results as easy as possible. A detailed Breast Recurrence Score report is generated for each patient. The report contains the Recurrence Score result—a number between 0-100—that assesses the 9-year risk of distant recurrence1 in node-negative patients, 5-year distant recurrence or mortality in node-positive3 patients and the likelihood that chemotherapy will benefit your patient.2,4

Interactive Report Guide

A quick and intuitive explanation of what to look for in each Breast Recurrence Score report.

The relevance of the ER score

The quantitative ER score by RT-PCR has been shown to be a strong predictor of tamoxifen benefit5 in node-negative patients. While the Recurrence Score result and corresponding average rate of distant recurrence accounts for this effect of tamoxifen (in addition to the tumor’s fundamental prognosis), the single-gene ER score may also help clarify the magnitude of tamoxifen benefit.

How your patient’s score is generated

The Breast Recurrence Score test is a genomic test—that measures the expression of cancer-related genes in your patient’s tumor. Your patient’s score is based on the expression of 21 specific genes from tumor tissue removed during the surgery or core biopsy. Looking at the expression of this unique set of genes the score provides important information about how likely your patient’s cancer is to return and the likelihood of benefit from chemotherapy. Learn more about how the test works.

Getting the results

Most Recurrence Score results are available within two weeks from the date the specimen is received in the Genomic Health lab. You can access the results through the online physician portal or receive the report by fax.

START REPORT GUIDE
START REPORT GUIDE
START REPORT GUIDE
START REPORT GUIDE
REFERENCES

1. Paik et al. N Engl J Med. 2004.
2. Paik et al. J Clin Oncol. 2006.
3. Dowsett et al. J Clin Oncol. 2010.
4. Albain et al. Lancet Oncol. 2010.
5. Kim et al. J Clin Oncol. 2010.

Prospective Outcomes:
TAILORxa

The Trial Assigning Individualized Options for Treatment (TAILORx) primary study group results were presented at the Plenary Session at ASCO 2018.

Read Full Text

Physician Portal

Access test results, archived cases, and more.

Sign In

Do You Have a Question?

Contact Us

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™